AstraZeneca (AZN) Announces ENHERTU Approved in EU as First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed .
/PRNewswire/ Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced an agreement with AstraZeneca and Daiichi Sankyo,.
Enhertu Approved by Health Canada as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer - read this article along with other careers information, tips and advice on BioSpace